Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial

Creative Commons License

Solomon S. D., Claggett B., Desai A. S., Packer M., Zile M., Swedberg K., ...More

CIRCULATION-HEART FAILURE, vol.9, no.3, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.1161/circheartfailure.115.002744
  • Journal Name: CIRCULATION-HEART FAILURE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: heart, heart failure, humans, mineralocorticoid receptor antagonists, neprilysin, INHIBITION, ENALAPRIL
  • Dokuz Eylül University Affiliated: Yes

Abstract

Background The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril.